JP2001288110A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001288110A5 JP2001288110A5 JP2000105531A JP2000105531A JP2001288110A5 JP 2001288110 A5 JP2001288110 A5 JP 2001288110A5 JP 2000105531 A JP2000105531 A JP 2000105531A JP 2000105531 A JP2000105531 A JP 2000105531A JP 2001288110 A5 JP2001288110 A5 JP 2001288110A5
- Authority
- JP
- Japan
- Prior art keywords
- pegylated interferon
- medicament
- use according
- patient
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010047761 Interferon-alpha Proteins 0.000 description 19
- 102000006992 Interferon-alpha Human genes 0.000 description 19
- 239000003814 drug Substances 0.000 description 19
- 102100040018 Interferon alpha-2 Human genes 0.000 description 12
- 108010079944 Interferon-alpha2b Proteins 0.000 description 12
- 102000014150 Interferons Human genes 0.000 description 11
- 108010050904 Interferons Proteins 0.000 description 11
- 229940079322 interferon Drugs 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 6
- 208000006265 Renal cell carcinoma Diseases 0.000 description 5
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28835999A | 1999-04-08 | 1999-04-08 | |
| US09/288,359 | 1999-04-08 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000105528A Division JP3712914B2 (ja) | 1999-04-08 | 2000-04-06 | 腎細胞ガン処置 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2001288110A JP2001288110A (ja) | 2001-10-16 |
| JP2001288110A6 JP2001288110A6 (ja) | 2006-12-07 |
| JP2001288110A5 true JP2001288110A5 (https=) | 2007-05-31 |
| JP4721488B2 JP4721488B2 (ja) | 2011-07-13 |
Family
ID=23106761
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000105528A Expired - Fee Related JP3712914B2 (ja) | 1999-04-08 | 2000-04-06 | 腎細胞ガン処置 |
| JP2000105531A Expired - Fee Related JP4721488B2 (ja) | 1999-04-08 | 2000-04-06 | 腎細胞ガン処置 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000105528A Expired - Fee Related JP3712914B2 (ja) | 1999-04-08 | 2000-04-06 | 腎細胞ガン処置 |
Country Status (23)
| Country | Link |
|---|---|
| EP (2) | EP1043025B1 (https=) |
| JP (2) | JP3712914B2 (https=) |
| CN (1) | CN1367702A (https=) |
| AR (1) | AR029160A1 (https=) |
| AT (2) | ATE296638T1 (https=) |
| AU (2) | AU777406B2 (https=) |
| BR (1) | BR0009644A (https=) |
| CA (1) | CA2303752A1 (https=) |
| CO (1) | CO5170412A1 (https=) |
| CY (1) | CY1108919T1 (https=) |
| DE (2) | DE60041291D1 (https=) |
| DK (2) | DK1043025T3 (https=) |
| ES (2) | ES2239953T3 (https=) |
| HU (1) | HU230271B1 (https=) |
| MX (1) | MXPA00003401A (https=) |
| MY (1) | MY155221A (https=) |
| NO (1) | NO328983B1 (https=) |
| NZ (1) | NZ514629A (https=) |
| PE (1) | PE20010026A1 (https=) |
| PT (2) | PT1043025E (https=) |
| TW (2) | TWI310314B (https=) |
| WO (1) | WO2000061174A2 (https=) |
| ZA (1) | ZA200108169B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2303752A1 (en) * | 1999-04-08 | 2000-10-08 | Schering Corporation | Renal cell carcinoma treatment |
| CA2648077A1 (en) * | 2006-03-31 | 2007-11-08 | Schering Corporation | Parenteral low dose type 1 interferons for bladder cancer |
| TW200901989A (en) * | 2007-04-10 | 2009-01-16 | Wyeth Corp | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
| US8053430B2 (en) | 2008-10-06 | 2011-11-08 | Haraldsson Boerje | Treatment of renal cell carcinoma |
| ES2891564T3 (es) | 2010-04-01 | 2022-01-28 | Oncorena Ab | Tratamiento mejorado del carcinoma de células renales |
| CN103463623B (zh) * | 2013-09-03 | 2015-09-09 | 长春海伯尔生物技术有限责任公司 | 一种聚乙二醇干扰素注射液及其制备方法 |
| BR112019024556A2 (pt) | 2017-05-24 | 2020-06-23 | Novartis Ag | Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer |
| WO2024186735A1 (en) * | 2023-03-03 | 2024-09-12 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for the treatment of cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766582A (en) * | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
| US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| WO1999048535A1 (en) * | 1998-03-26 | 1999-09-30 | Schering Corporation | Formulations for protection of peg-interferon alpha conjugates |
| CA2303752A1 (en) * | 1999-04-08 | 2000-10-08 | Schering Corporation | Renal cell carcinoma treatment |
-
2000
- 2000-04-06 CA CA002303752A patent/CA2303752A1/en not_active Abandoned
- 2000-04-06 CN CN00808740A patent/CN1367702A/zh active Pending
- 2000-04-06 AR ARP000101572A patent/AR029160A1/es unknown
- 2000-04-06 AU AU42044/00A patent/AU777406B2/en not_active Ceased
- 2000-04-06 DE DE60041291T patent/DE60041291D1/de not_active Expired - Lifetime
- 2000-04-06 CO CO00025239A patent/CO5170412A1/es not_active Application Discontinuation
- 2000-04-06 DK DK00107100T patent/DK1043025T3/da active
- 2000-04-06 JP JP2000105528A patent/JP3712914B2/ja not_active Expired - Fee Related
- 2000-04-06 AT AT00107100T patent/ATE296638T1/de active
- 2000-04-06 EP EP00107100A patent/EP1043025B1/en not_active Expired - Lifetime
- 2000-04-06 HU HU0200781A patent/HU230271B1/hu not_active IP Right Cessation
- 2000-04-06 DK DK05002952T patent/DK1535623T3/da active
- 2000-04-06 AT AT05002952T patent/ATE419002T1/de active
- 2000-04-06 MX MXPA00003401A patent/MXPA00003401A/es active IP Right Grant
- 2000-04-06 TW TW089106326A patent/TWI310314B/zh not_active IP Right Cessation
- 2000-04-06 DE DE60020442T patent/DE60020442T2/de not_active Expired - Lifetime
- 2000-04-06 NZ NZ514629A patent/NZ514629A/xx not_active IP Right Cessation
- 2000-04-06 ES ES00107100T patent/ES2239953T3/es not_active Expired - Lifetime
- 2000-04-06 TW TW094103729A patent/TW200526243A/zh unknown
- 2000-04-06 BR BR0009644-0A patent/BR0009644A/pt not_active Application Discontinuation
- 2000-04-06 EP EP05002952A patent/EP1535623B1/en not_active Expired - Lifetime
- 2000-04-06 WO PCT/US2000/009127 patent/WO2000061174A2/en not_active Ceased
- 2000-04-06 ES ES05002952T patent/ES2319777T3/es not_active Expired - Lifetime
- 2000-04-06 PT PT00107100T patent/PT1043025E/pt unknown
- 2000-04-06 JP JP2000105531A patent/JP4721488B2/ja not_active Expired - Fee Related
- 2000-04-06 PT PT05002952T patent/PT1535623E/pt unknown
- 2000-04-07 MY MYPI20001452A patent/MY155221A/en unknown
- 2000-04-07 PE PE2000000316A patent/PE20010026A1/es not_active Application Discontinuation
-
2001
- 2001-10-04 ZA ZA200108169A patent/ZA200108169B/en unknown
- 2001-10-05 NO NO20014851A patent/NO328983B1/no not_active IP Right Cessation
-
2004
- 2004-12-23 AU AU2004242454A patent/AU2004242454B2/en not_active Ceased
-
2009
- 2009-03-24 CY CY20091100350T patent/CY1108919T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2000037110A3 (en) | Ribavirin-pegylated interferon alfa induction hcv combination therapy | |
| RU2011139180A (ru) | Комбинация нуклеозидного ингибитора полимеразы и макроциклического ингибитора протеазы и ее применение для лечения гепатита с, фиброза печени и нарушенной печеночной функции | |
| CA2580448A1 (en) | Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3-[etval]4-cyclosporin | |
| JP2001515712A5 (https=) | ||
| CA2245938A1 (en) | Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection | |
| JP2002515453A5 (https=) | ||
| RU2002127804A (ru) | Лекарственная система для лечения осложнений, связанных с диабетом, и невропатии, и их применения | |
| JP2002523370A5 (https=) | ||
| JP2002528502A5 (https=) | ||
| JP2004537500A5 (https=) | ||
| IL161889A (en) | Use of omega interferon in the manufacture of a medicament for treating viral disease | |
| WO2005011579A3 (en) | Treatment of dependence withdrawal | |
| KR20110053327A (ko) | 텔라프레비르 투여 방식 | |
| EP4494701A3 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| JP2001288110A5 (https=) | ||
| JP2005508896A5 (https=) | ||
| JP2002523437A5 (https=) | ||
| JP2003514025A5 (https=) | ||
| RU2005126819A (ru) | Усовершенствованное лечение опухолей | |
| RU2371195C2 (ru) | Способ лечения вирусных инфекций | |
| JP2002530353A5 (https=) | ||
| WO2001012214A3 (en) | MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a) | |
| Zein | Interferons in the management of viral hepatitis | |
| JP2007501806A5 (https=) | ||
| NZ514629A (en) | PEGylated interferon-alpha administered at about 4.5- 9.0 micrograms/kg/week as a renal cell carcinoma treatment |